We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.005 | 0.25% | 2.04 | 2.01 | 2.07 | 2.10 | 2.09 | 2.09 | 477,122 | 16:35:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.84 | 7M |
TIDMIMM
RNS Number : 6273A
Immupharma PLC
30 September 2015
FOR IMMEDIATE RELEASE 30 SEPTEMBER 2015
TIM MCCARTHY APPOINTED AS NON-EXECUTIVE CHAIRMAN
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect.
Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera, Harvard Healthcare and Expedeon Holdings. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.
A Fellow of the Association of Chartered Certified Accountants, Mr McCarthy has an MBA from Cranfield School of Management.
Commenting on Tim McCarthy's appointment, Dimitri Dimitrou, Chief Executive Officer, said:
"We are delighted to have Tim join ImmuPharma as Chairman. This appointment represents a further strong addition to the Board. Tim's commercial and industry background together with capital markets experience will be extremely valuable as ImmuPharma progresses its lead compound, Lupuzor(TM) , through its pivotal Phase III trial, as well as providing guidance on ImmuPharma's long term business strategy."
Current Directorships
Ark Analytics Solutions Limited
BBN International Limited
Dropped Limited
Expedeon Holdings Limited
Frangipani Dreams Limited
Harvard Healthcare Limited
Incanthera Limited
Spear Therapeutics Limited
Unnamed Limited
Wise Old Owl Limited
Directorships in the Last 5 years
Retail Service Team Limited*
*This company entered into a Creditors Voluntary Winding-up on 12(th) December 2013, 8 months after Mr McCarthy's resignation of directorship. It was dissolved on 4 June 2015.
There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.
For further information please contact:
+ 44 (0) 20 ImmuPharma plc 7152 4080 Dimitri Dimitriou, Chief Executive Officer Lisa Baderoon, Head of Investor + 44 (0) 7721 Relations 413 496 Panmure, Gordon & Co., NOMAD & + 44 (0) 20 Broker 7886 2500 Fred Walsh, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAPKCDNOBKDNCB
(END) Dow Jones Newswires
September 30, 2015 02:05 ET (06:05 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions